CN1582330A - 体外微器官及其相关用途 - Google Patents
体外微器官及其相关用途 Download PDFInfo
- Publication number
- CN1582330A CN1582330A CNA018239064A CN01823906A CN1582330A CN 1582330 A CN1582330 A CN 1582330A CN A018239064 A CNA018239064 A CN A018239064A CN 01823906 A CN01823906 A CN 01823906A CN 1582330 A CN1582330 A CN 1582330A
- Authority
- CN
- China
- Prior art keywords
- micro
- organs
- explant
- cell
- organ
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 238000000338 in vitro Methods 0.000 title description 17
- 210000004027 cell Anatomy 0.000 claims abstract description 426
- 238000000034 method Methods 0.000 claims abstract description 159
- 210000000056 organ Anatomy 0.000 claims abstract description 136
- 108090000623 proteins and genes Proteins 0.000 claims abstract description 90
- 210000003491 skin Anatomy 0.000 claims description 122
- 206010020718 hyperplasia Diseases 0.000 claims description 109
- 210000001519 tissue Anatomy 0.000 claims description 107
- 210000000496 pancreas Anatomy 0.000 claims description 59
- 150000007523 nucleic acids Chemical group 0.000 claims description 55
- 210000003780 hair follicle Anatomy 0.000 claims description 49
- 241000700605 Viruses Species 0.000 claims description 47
- 210000000981 epithelium Anatomy 0.000 claims description 35
- 241001465754 Metazoa Species 0.000 claims description 33
- 238000001890 transfection Methods 0.000 claims description 32
- 210000004185 liver Anatomy 0.000 claims description 31
- 239000011159 matrix material Substances 0.000 claims description 31
- 230000006798 recombination Effects 0.000 claims description 30
- 238000005215 recombination Methods 0.000 claims description 30
- -1 rnase Proteins 0.000 claims description 22
- 210000001541 thymus gland Anatomy 0.000 claims description 21
- 230000035764 nutrition Effects 0.000 claims description 20
- 235000016709 nutrition Nutrition 0.000 claims description 20
- 230000001413 cellular effect Effects 0.000 claims description 19
- 210000004907 gland Anatomy 0.000 claims description 19
- 230000006870 function Effects 0.000 claims description 18
- 230000009385 viral infection Effects 0.000 claims description 18
- 102000004877 Insulin Human genes 0.000 claims description 17
- 108090001061 Insulin Proteins 0.000 claims description 17
- 108090000723 Insulin-Like Growth Factor I Proteins 0.000 claims description 17
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims description 17
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims description 17
- 102000013275 Somatomedins Human genes 0.000 claims description 17
- 239000000463 material Substances 0.000 claims description 15
- 210000003734 kidney Anatomy 0.000 claims description 13
- 239000002609 medium Substances 0.000 claims description 13
- 238000004520 electroporation Methods 0.000 claims description 12
- 102000004169 proteins and genes Human genes 0.000 claims description 12
- 210000000952 spleen Anatomy 0.000 claims description 12
- 230000009261 transgenic effect Effects 0.000 claims description 12
- 210000004369 blood Anatomy 0.000 claims description 11
- 239000008280 blood Substances 0.000 claims description 11
- 231100000135 cytotoxicity Toxicity 0.000 claims description 11
- 230000003013 cytotoxicity Effects 0.000 claims description 11
- 230000001404 mediated effect Effects 0.000 claims description 11
- 241001430294 unidentified retrovirus Species 0.000 claims description 11
- 239000004382 Amylase Substances 0.000 claims description 10
- 102000013142 Amylases Human genes 0.000 claims description 10
- 108010065511 Amylases Proteins 0.000 claims description 10
- 235000019418 amylase Nutrition 0.000 claims description 10
- 241000701161 unidentified adenovirus Species 0.000 claims description 10
- 239000003636 conditioned culture medium Substances 0.000 claims description 9
- 239000002502 liposome Substances 0.000 claims description 9
- 239000002699 waste material Substances 0.000 claims description 9
- 229920002307 Dextran Polymers 0.000 claims description 8
- 102000004190 Enzymes Human genes 0.000 claims description 8
- 108090000790 Enzymes Proteins 0.000 claims description 8
- 238000009792 diffusion process Methods 0.000 claims description 8
- 229940088598 enzyme Drugs 0.000 claims description 8
- 208000006454 hepatitis Diseases 0.000 claims description 8
- 231100000283 hepatitis Toxicity 0.000 claims description 8
- 238000002347 injection Methods 0.000 claims description 7
- 239000007924 injection Substances 0.000 claims description 7
- 210000000232 gallbladder Anatomy 0.000 claims description 6
- 102000005962 receptors Human genes 0.000 claims description 6
- 108020003175 receptors Proteins 0.000 claims description 6
- ZIIUUSVHCHPIQD-UHFFFAOYSA-N 2,4,6-trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide Chemical compound CC1=CC(C)=CC(C)=C1S(=O)(=O)NC1=CC=CC(C(F)(F)F)=C1 ZIIUUSVHCHPIQD-UHFFFAOYSA-N 0.000 claims description 5
- 108010006303 Carboxypeptidases Proteins 0.000 claims description 5
- 102000005367 Carboxypeptidases Human genes 0.000 claims description 5
- 108010038061 Chymotrypsinogen Proteins 0.000 claims description 5
- 108010003422 Circulating Thymic Factor Proteins 0.000 claims description 5
- 102000002004 Cytochrome P-450 Enzyme System Human genes 0.000 claims description 5
- 108010015742 Cytochrome P-450 Enzyme System Proteins 0.000 claims description 5
- 241000701022 Cytomegalovirus Species 0.000 claims description 5
- 102000016911 Deoxyribonucleases Human genes 0.000 claims description 5
- 108010053770 Deoxyribonucleases Proteins 0.000 claims description 5
- 102000018233 Fibroblast Growth Factor Human genes 0.000 claims description 5
- 108050007372 Fibroblast Growth Factor Proteins 0.000 claims description 5
- 108010052343 Gastrins Proteins 0.000 claims description 5
- 102000016354 Glucuronosyltransferase Human genes 0.000 claims description 5
- 108010092364 Glucuronosyltransferase Proteins 0.000 claims description 5
- 102000015696 Interleukins Human genes 0.000 claims description 5
- 108010063738 Interleukins Proteins 0.000 claims description 5
- 102100023981 Lamina-associated polypeptide 2, isoform alpha Human genes 0.000 claims description 5
- 101710163560 Lamina-associated polypeptide 2, isoform alpha Proteins 0.000 claims description 5
- 101710189385 Lamina-associated polypeptide 2, isoforms beta/gamma Proteins 0.000 claims description 5
- 102000004882 Lipase Human genes 0.000 claims description 5
- 108090001060 Lipase Proteins 0.000 claims description 5
- 239000004367 Lipase Substances 0.000 claims description 5
- 102000007981 Ornithine carbamoyltransferase Human genes 0.000 claims description 5
- 101710198224 Ornithine carbamoyltransferase, mitochondrial Proteins 0.000 claims description 5
- 102000035195 Peptidases Human genes 0.000 claims description 5
- 108091005804 Peptidases Proteins 0.000 claims description 5
- 102000015439 Phospholipases Human genes 0.000 claims description 5
- 108010064785 Phospholipases Proteins 0.000 claims description 5
- 102000005157 Somatostatin Human genes 0.000 claims description 5
- 108010056088 Somatostatin Proteins 0.000 claims description 5
- 108090000190 Thrombin Proteins 0.000 claims description 5
- 239000000898 Thymopoietin Substances 0.000 claims description 5
- 108010027252 Trypsinogen Proteins 0.000 claims description 5
- 102000018690 Trypsinogen Human genes 0.000 claims description 5
- 238000010521 absorption reaction Methods 0.000 claims description 5
- 239000001506 calcium phosphate Substances 0.000 claims description 5
- 229910000389 calcium phosphate Inorganic materials 0.000 claims description 5
- 235000011010 calcium phosphates Nutrition 0.000 claims description 5
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 claims description 5
- 229940126864 fibroblast growth factor Drugs 0.000 claims description 5
- 235000019421 lipase Nutrition 0.000 claims description 5
- 210000005210 lymphoid organ Anatomy 0.000 claims description 5
- 210000004798 organs belonging to the digestive system Anatomy 0.000 claims description 5
- 230000001850 reproductive effect Effects 0.000 claims description 5
- 229960000553 somatostatin Drugs 0.000 claims description 5
- NHXLMOGPVYXJNR-ATOGVRKGSA-N somatostatin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CC=2C3=CC=CC=C3NC=2)C(=O)N[C@@H](CCCCN)C(=O)N[C@H](C(=O)N1)[C@@H](C)O)NC(=O)CNC(=O)[C@H](C)N)C(O)=O)=O)[C@H](O)C)C1=CC=CC=C1 NHXLMOGPVYXJNR-ATOGVRKGSA-N 0.000 claims description 5
- 229960004072 thrombin Drugs 0.000 claims description 5
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 claims description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 5
- 210000001635 urinary tract Anatomy 0.000 claims description 5
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 5
- 101710169336 5'-deoxyadenosine deaminase Proteins 0.000 claims description 4
- 102000055025 Adenosine deaminases Human genes 0.000 claims description 4
- 101800001982 Cholecystokinin Proteins 0.000 claims description 4
- 102100025841 Cholecystokinin Human genes 0.000 claims description 4
- 102000003951 Erythropoietin Human genes 0.000 claims description 4
- 108090000394 Erythropoietin Proteins 0.000 claims description 4
- 241001631646 Papillomaviridae Species 0.000 claims description 4
- 102100037505 Secretin Human genes 0.000 claims description 4
- 108010086019 Secretin Proteins 0.000 claims description 4
- 108091023040 Transcription factor Proteins 0.000 claims description 4
- 102000040945 Transcription factor Human genes 0.000 claims description 4
- 229940107137 cholecystokinin Drugs 0.000 claims description 4
- 108010036027 erythrogenin Proteins 0.000 claims description 4
- 229940105423 erythropoietin Drugs 0.000 claims description 4
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims description 4
- 210000002345 respiratory system Anatomy 0.000 claims description 4
- 229960002101 secretin Drugs 0.000 claims description 4
- OWMZNFCDEHGFEP-NFBCVYDUSA-N secretin human Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(N)=O)[C@@H](C)O)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)C1=CC=CC=C1 OWMZNFCDEHGFEP-NFBCVYDUSA-N 0.000 claims description 4
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 claims description 4
- YTQVHRVITVLIRD-UHFFFAOYSA-L thallium sulfate Chemical compound [Tl+].[Tl+].[O-]S([O-])(=O)=O YTQVHRVITVLIRD-UHFFFAOYSA-L 0.000 claims description 4
- 230000009466 transformation Effects 0.000 claims description 4
- 241000702421 Dependoparvovirus Species 0.000 claims description 3
- 238000012239 gene modification Methods 0.000 claims 34
- 230000005017 genetic modification Effects 0.000 claims 34
- 235000013617 genetically modified food Nutrition 0.000 claims 34
- 102100021022 Gastrin Human genes 0.000 claims 3
- 102000009618 Transforming Growth Factors Human genes 0.000 claims 3
- 108010009583 Transforming Growth Factors Proteins 0.000 claims 3
- 230000008521 reorganization Effects 0.000 claims 3
- 241001529453 unidentified herpesvirus Species 0.000 claims 3
- 102000007527 Autoreceptors Human genes 0.000 claims 1
- 108010071131 Autoreceptors Proteins 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 210000000130 stem cell Anatomy 0.000 abstract description 34
- 239000003112 inhibitor Substances 0.000 abstract description 22
- 239000003795 chemical substances by application Substances 0.000 abstract description 18
- 230000003612 virological effect Effects 0.000 abstract description 17
- 230000002062 proliferating effect Effects 0.000 abstract description 8
- 230000024245 cell differentiation Effects 0.000 abstract description 7
- 238000004321 preservation Methods 0.000 abstract description 5
- 230000004663 cell proliferation Effects 0.000 abstract description 4
- 238000002054 transplantation Methods 0.000 abstract description 3
- 230000008611 intercellular interaction Effects 0.000 abstract description 2
- 230000008619 cell matrix interaction Effects 0.000 abstract 1
- 238000002955 isolation Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 65
- 150000001875 compounds Chemical class 0.000 description 58
- 108020004707 nucleic acids Proteins 0.000 description 52
- 102000039446 nucleic acids Human genes 0.000 description 52
- 108020004414 DNA Proteins 0.000 description 45
- 230000012010 growth Effects 0.000 description 45
- 210000002615 epidermis Anatomy 0.000 description 37
- 239000003153 chemical reaction reagent Substances 0.000 description 29
- 206010028980 Neoplasm Diseases 0.000 description 26
- 208000027418 Wounds and injury Diseases 0.000 description 25
- 230000004069 differentiation Effects 0.000 description 25
- 210000002919 epithelial cell Anatomy 0.000 description 25
- 230000001105 regulatory effect Effects 0.000 description 25
- 230000000694 effects Effects 0.000 description 24
- 210000004209 hair Anatomy 0.000 description 24
- 206010052428 Wound Diseases 0.000 description 23
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 22
- 230000014509 gene expression Effects 0.000 description 22
- 239000010410 layer Substances 0.000 description 21
- 238000002360 preparation method Methods 0.000 description 20
- 239000000203 mixture Substances 0.000 description 19
- 238000012360 testing method Methods 0.000 description 19
- WOVKYSAHUYNSMH-RRKCRQDMSA-N 5-bromodeoxyuridine Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(Br)=C1 WOVKYSAHUYNSMH-RRKCRQDMSA-N 0.000 description 18
- 210000002966 serum Anatomy 0.000 description 18
- 201000011510 cancer Diseases 0.000 description 17
- 238000001727 in vivo Methods 0.000 description 17
- 230000008569 process Effects 0.000 description 17
- 241000699666 Mus <mouse, genus> Species 0.000 description 16
- 238000001514 detection method Methods 0.000 description 15
- 238000005516 engineering process Methods 0.000 description 14
- 239000007943 implant Substances 0.000 description 14
- 230000008676 import Effects 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 238000011160 research Methods 0.000 description 14
- 108060001084 Luciferase Proteins 0.000 description 13
- 239000003814 drug Substances 0.000 description 13
- 210000002510 keratinocyte Anatomy 0.000 description 13
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 12
- 230000008859 change Effects 0.000 description 12
- 208000035475 disorder Diseases 0.000 description 12
- 239000000284 extract Substances 0.000 description 12
- 239000013612 plasmid Substances 0.000 description 12
- 201000004681 Psoriasis Diseases 0.000 description 11
- 241000282898 Sus scrofa Species 0.000 description 11
- 239000000758 substrate Substances 0.000 description 11
- 210000000106 sweat gland Anatomy 0.000 description 11
- 239000005089 Luciferase Substances 0.000 description 10
- 238000013459 approach Methods 0.000 description 10
- 201000010099 disease Diseases 0.000 description 10
- 230000003779 hair growth Effects 0.000 description 10
- 210000004919 hair shaft Anatomy 0.000 description 10
- 230000001939 inductive effect Effects 0.000 description 10
- 210000004072 lung Anatomy 0.000 description 10
- 230000028327 secretion Effects 0.000 description 10
- 108700008625 Reporter Genes Proteins 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- 210000000442 hair follicle cell Anatomy 0.000 description 9
- 230000035876 healing Effects 0.000 description 9
- 230000013632 homeostatic process Effects 0.000 description 9
- 210000004153 islets of langerhan Anatomy 0.000 description 9
- 238000000926 separation method Methods 0.000 description 9
- 201000004384 Alopecia Diseases 0.000 description 8
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 8
- 239000006144 Dulbecco’s modified Eagle's medium Substances 0.000 description 8
- 230000008929 regeneration Effects 0.000 description 8
- 238000011069 regeneration method Methods 0.000 description 8
- 239000000523 sample Substances 0.000 description 8
- 239000013598 vector Substances 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 238000005520 cutting process Methods 0.000 description 7
- 230000002950 deficient Effects 0.000 description 7
- 238000002474 experimental method Methods 0.000 description 7
- 230000036541 health Effects 0.000 description 7
- 230000000394 mitotic effect Effects 0.000 description 7
- 230000008520 organization Effects 0.000 description 7
- 230000003076 paracrine Effects 0.000 description 7
- 230000002269 spontaneous effect Effects 0.000 description 7
- 210000000438 stratum basale Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 210000003932 urinary bladder Anatomy 0.000 description 7
- 241000700199 Cavia porcellus Species 0.000 description 6
- 102000004887 Transforming Growth Factor beta Human genes 0.000 description 6
- 108090001012 Transforming Growth Factor beta Proteins 0.000 description 6
- 230000004913 activation Effects 0.000 description 6
- 239000000427 antigen Substances 0.000 description 6
- 108091007433 antigens Proteins 0.000 description 6
- 102000036639 antigens Human genes 0.000 description 6
- 230000003305 autocrine Effects 0.000 description 6
- 230000008901 benefit Effects 0.000 description 6
- 230000001684 chronic effect Effects 0.000 description 6
- 210000004087 cornea Anatomy 0.000 description 6
- 238000001415 gene therapy Methods 0.000 description 6
- 238000010166 immunofluorescence Methods 0.000 description 6
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 6
- 230000003993 interaction Effects 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000012679 serum free medium Substances 0.000 description 6
- ZRKFYGHZFMAOKI-QMGMOQQFSA-N tgfbeta Chemical compound C([C@H](NC(=O)[C@H](C(C)C)NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H]([C@@H](C)O)NC(=O)[C@H](CC(C)C)NC(=O)CNC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](C)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CCSC)C(C)C)[C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(O)=O)C1=CC=C(O)C=C1 ZRKFYGHZFMAOKI-QMGMOQQFSA-N 0.000 description 6
- 229940104230 thymidine Drugs 0.000 description 6
- 230000029663 wound healing Effects 0.000 description 6
- 102000008186 Collagen Human genes 0.000 description 5
- 108010035532 Collagen Proteins 0.000 description 5
- 241000700721 Hepatitis B virus Species 0.000 description 5
- 108010076876 Keratins Proteins 0.000 description 5
- 241000283984 Rodentia Species 0.000 description 5
- IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 5
- 231100000360 alopecia Toxicity 0.000 description 5
- 235000019994 cava Nutrition 0.000 description 5
- 230000022131 cell cycle Effects 0.000 description 5
- 230000010261 cell growth Effects 0.000 description 5
- 229920001436 collagen Polymers 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 229940079593 drug Drugs 0.000 description 5
- 210000001198 duodenum Anatomy 0.000 description 5
- 229940088597 hormone Drugs 0.000 description 5
- 239000005556 hormone Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000007774 longterm Effects 0.000 description 5
- 230000004048 modification Effects 0.000 description 5
- 238000012986 modification Methods 0.000 description 5
- 230000035407 negative regulation of cell proliferation Effects 0.000 description 5
- 229920001778 nylon Polymers 0.000 description 5
- 230000010355 oscillation Effects 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 230000010076 replication Effects 0.000 description 5
- 238000012216 screening Methods 0.000 description 5
- 230000002459 sustained effect Effects 0.000 description 5
- 241000283707 Capra Species 0.000 description 4
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 4
- 241000701806 Human papillomavirus Species 0.000 description 4
- 102000011782 Keratins Human genes 0.000 description 4
- 241001071864 Lethrinus laticaudis Species 0.000 description 4
- 239000004677 Nylon Substances 0.000 description 4
- 229930182555 Penicillin Natural products 0.000 description 4
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 4
- 108020004511 Recombinant DNA Proteins 0.000 description 4
- 206010040943 Skin Ulcer Diseases 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 4
- 238000004458 analytical method Methods 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 4
- 238000006243 chemical reaction Methods 0.000 description 4
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000007547 defect Effects 0.000 description 4
- 206010012601 diabetes mellitus Diseases 0.000 description 4
- 238000010586 diagram Methods 0.000 description 4
- 239000000975 dye Substances 0.000 description 4
- 238000004043 dyeing Methods 0.000 description 4
- 239000008103 glucose Substances 0.000 description 4
- 208000002672 hepatitis B Diseases 0.000 description 4
- 230000001965 increasing effect Effects 0.000 description 4
- 230000006698 induction Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- 239000003446 ligand Substances 0.000 description 4
- 238000001638 lipofection Methods 0.000 description 4
- 210000004962 mammalian cell Anatomy 0.000 description 4
- 238000000520 microinjection Methods 0.000 description 4
- 238000010369 molecular cloning Methods 0.000 description 4
- 125000003729 nucleotide group Chemical group 0.000 description 4
- 229940049954 penicillin Drugs 0.000 description 4
- 239000002243 precursor Substances 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 210000002307 prostate Anatomy 0.000 description 4
- 210000004927 skin cell Anatomy 0.000 description 4
- 238000010561 standard procedure Methods 0.000 description 4
- 230000003068 static effect Effects 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 4
- 238000012546 transfer Methods 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- 101710112752 Cytotoxin Proteins 0.000 description 3
- 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 3
- 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 3
- 102000051325 Glucagon Human genes 0.000 description 3
- 108060003199 Glucagon Proteins 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 3
- 241000725303 Human immunodeficiency virus Species 0.000 description 3
- 206010062767 Hypophysitis Diseases 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 241000700584 Simplexvirus Species 0.000 description 3
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 3
- HMNZFMSWFCAGGW-XPWSMXQVSA-N [3-[hydroxy(2-hydroxyethoxy)phosphoryl]oxy-2-[(e)-octadec-9-enoyl]oxypropyl] (e)-octadec-9-enoate Chemical compound CCCCCCCC\C=C\CCCCCCCC(=O)OCC(COP(O)(=O)OCCO)OC(=O)CCCCCCC\C=C\CCCCCCCC HMNZFMSWFCAGGW-XPWSMXQVSA-N 0.000 description 3
- 210000000577 adipose tissue Anatomy 0.000 description 3
- 230000032683 aging Effects 0.000 description 3
- 230000000840 anti-viral effect Effects 0.000 description 3
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 description 3
- 102000005936 beta-Galactosidase Human genes 0.000 description 3
- 108010005774 beta-Galactosidase Proteins 0.000 description 3
- 210000000013 bile duct Anatomy 0.000 description 3
- 210000003443 bladder cell Anatomy 0.000 description 3
- 210000004204 blood vessel Anatomy 0.000 description 3
- 210000000481 breast Anatomy 0.000 description 3
- 239000002729 catgut Substances 0.000 description 3
- 230000003915 cell function Effects 0.000 description 3
- 230000011748 cell maturation Effects 0.000 description 3
- 230000008614 cellular interaction Effects 0.000 description 3
- 210000004748 cultured cell Anatomy 0.000 description 3
- 238000012258 culturing Methods 0.000 description 3
- 231100000433 cytotoxic Toxicity 0.000 description 3
- 231100000599 cytotoxic agent Toxicity 0.000 description 3
- 230000001472 cytotoxic effect Effects 0.000 description 3
- 239000002619 cytotoxin Substances 0.000 description 3
- 238000013461 design Methods 0.000 description 3
- 210000003981 ectoderm Anatomy 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- 210000002744 extracellular matrix Anatomy 0.000 description 3
- 239000000835 fiber Substances 0.000 description 3
- 230000003328 fibroblastic effect Effects 0.000 description 3
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 3
- 238000011010 flushing procedure Methods 0.000 description 3
- 230000003325 follicular Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- MASNOZXLGMXCHN-ZLPAWPGGSA-N glucagon Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CO)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC=1NC=NC=1)[C@@H](C)O)[C@@H](C)O)C1=CC=CC=C1 MASNOZXLGMXCHN-ZLPAWPGGSA-N 0.000 description 3
- 229960004666 glucagon Drugs 0.000 description 3
- 239000001963 growth medium Substances 0.000 description 3
- 230000002390 hyperplastic effect Effects 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 229940125396 insulin Drugs 0.000 description 3
- 150000002500 ions Chemical class 0.000 description 3
- 210000005229 liver cell Anatomy 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 210000005075 mammary gland Anatomy 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000007758 minimum essential medium Substances 0.000 description 3
- 210000005036 nerve Anatomy 0.000 description 3
- 238000001556 precipitation Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 238000010839 reverse transcription Methods 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 238000011654 sencar mouse Methods 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 206010041823 squamous cell carcinoma Diseases 0.000 description 3
- 238000010186 staining Methods 0.000 description 3
- 230000004083 survival effect Effects 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 210000004291 uterus Anatomy 0.000 description 3
- 230000002792 vascular Effects 0.000 description 3
- 210000002845 virion Anatomy 0.000 description 3
- 210000001835 viscera Anatomy 0.000 description 3
- 108010088751 Albumins Proteins 0.000 description 2
- 102000009027 Albumins Human genes 0.000 description 2
- 208000023095 Autosomal dominant epidermolytic ichthyosis Diseases 0.000 description 2
- DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 241001517488 Clavus Species 0.000 description 2
- 229920000742 Cotton Polymers 0.000 description 2
- 108010069091 Dystrophin Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 201000009040 Epidermolytic Hyperkeratosis Diseases 0.000 description 2
- 108010054218 Factor VIII Proteins 0.000 description 2
- 102000001690 Factor VIII Human genes 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- 230000005526 G1 to G0 transition Effects 0.000 description 2
- 102400000921 Gastrin Human genes 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 206010066476 Haematological malignancy Diseases 0.000 description 2
- 241000711549 Hepacivirus C Species 0.000 description 2
- 206010020112 Hirsutism Diseases 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
- 208000008771 Lymphadenopathy Diseases 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 239000004793 Polystyrene Substances 0.000 description 2
- 230000018199 S phase Effects 0.000 description 2
- 206010039491 Sarcoma Diseases 0.000 description 2
- 229920004933 Terylene® Polymers 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 208000013228 adenopathy Diseases 0.000 description 2
- OIRDTQYFTABQOQ-KQYNXXCUSA-N adenosine Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 description 2
- 210000001789 adipocyte Anatomy 0.000 description 2
- 229940072056 alginate Drugs 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 230000002547 anomalous effect Effects 0.000 description 2
- 210000000436 anus Anatomy 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 2
- 230000000975 bioactive effect Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 238000001574 biopsy Methods 0.000 description 2
- 239000012888 bovine serum Substances 0.000 description 2
- 210000004556 brain Anatomy 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000004202 carbamide Substances 0.000 description 2
- 230000023402 cell communication Effects 0.000 description 2
- 230000011712 cell development Effects 0.000 description 2
- 230000003833 cell viability Effects 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 235000012000 cholesterol Nutrition 0.000 description 2
- 238000004140 cleaning Methods 0.000 description 2
- 239000011248 coating agent Substances 0.000 description 2
- 238000000576 coating method Methods 0.000 description 2
- 210000001072 colon Anatomy 0.000 description 2
- 238000004891 communication Methods 0.000 description 2
- 230000006854 communication Effects 0.000 description 2
- 239000002299 complementary DNA Substances 0.000 description 2
- 230000007850 degeneration Effects 0.000 description 2
- 230000001066 destructive effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 238000003745 diagnosis Methods 0.000 description 2
- 230000001079 digestive effect Effects 0.000 description 2
- 238000007877 drug screening Methods 0.000 description 2
- 230000005684 electric field Effects 0.000 description 2
- 210000002308 embryonic cell Anatomy 0.000 description 2
- 210000003725 endotheliocyte Anatomy 0.000 description 2
- 230000036566 epidermal hyperplasia Effects 0.000 description 2
- 210000002514 epidermal stem cell Anatomy 0.000 description 2
- 208000033286 epidermolytic ichthyosis Diseases 0.000 description 2
- 230000008472 epithelial growth Effects 0.000 description 2
- 210000003527 eukaryotic cell Anatomy 0.000 description 2
- 239000013604 expression vector Substances 0.000 description 2
- 210000001508 eye Anatomy 0.000 description 2
- 230000004992 fission Effects 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 210000003953 foreskin Anatomy 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 238000010353 genetic engineering Methods 0.000 description 2
- 210000001357 hemopoietic progenitor cell Anatomy 0.000 description 2
- 210000004276 hyalin Anatomy 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 description 2
- 206010021198 ichthyosis Diseases 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 238000003365 immunocytochemistry Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 230000008595 infiltration Effects 0.000 description 2
- 238000001764 infiltration Methods 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 230000035992 intercellular communication Effects 0.000 description 2
- 230000003908 liver function Effects 0.000 description 2
- 238000012423 maintenance Methods 0.000 description 2
- 210000001161 mammalian embryo Anatomy 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- 238000002156 mixing Methods 0.000 description 2
- 238000004264 monolayer culture Methods 0.000 description 2
- 210000002200 mouth mucosa Anatomy 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 230000002107 myocardial effect Effects 0.000 description 2
- DILRJUIACXKSQE-UHFFFAOYSA-N n',n'-dimethylethane-1,2-diamine Chemical compound CN(C)CCN DILRJUIACXKSQE-UHFFFAOYSA-N 0.000 description 2
- 210000003928 nasal cavity Anatomy 0.000 description 2
- 230000001613 neoplastic effect Effects 0.000 description 2
- 230000001537 neural effect Effects 0.000 description 2
- 239000002773 nucleotide Substances 0.000 description 2
- 210000000287 oocyte Anatomy 0.000 description 2
- 210000002488 outer root sheath cell Anatomy 0.000 description 2
- 230000001936 parietal effect Effects 0.000 description 2
- 230000032696 parturition Effects 0.000 description 2
- 230000004962 physiological condition Effects 0.000 description 2
- 229920002401 polyacrylamide Polymers 0.000 description 2
- 239000005020 polyethylene terephthalate Substances 0.000 description 2
- 229920002223 polystyrene Polymers 0.000 description 2
- 239000004800 polyvinyl chloride Substances 0.000 description 2
- 229920000915 polyvinyl chloride Polymers 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 210000001187 pylorus Anatomy 0.000 description 2
- 238000000163 radioactive labelling Methods 0.000 description 2
- 230000010837 receptor-mediated endocytosis Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000008263 repair mechanism Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 230000000717 retained effect Effects 0.000 description 2
- 230000001177 retroviral effect Effects 0.000 description 2
- 210000004918 root sheath Anatomy 0.000 description 2
- 210000002374 sebum Anatomy 0.000 description 2
- 230000003248 secreting effect Effects 0.000 description 2
- 238000004088 simulation Methods 0.000 description 2
- 230000008470 skin growth Effects 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 229960005322 streptomycin Drugs 0.000 description 2
- QTENRWWVYAAPBI-YCRXJPFRSA-N streptomycin sulfate Chemical compound OS(O)(=O)=O.OS(O)(=O)=O.OS(O)(=O)=O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O.CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](N=C(N)N)[C@H](O)[C@@H](N=C(N)N)[C@H](O)[C@H]1O QTENRWWVYAAPBI-YCRXJPFRSA-N 0.000 description 2
- 210000002536 stromal cell Anatomy 0.000 description 2
- 239000003104 tissue culture media Substances 0.000 description 2
- 231100000331 toxic Toxicity 0.000 description 2
- 230000002588 toxic effect Effects 0.000 description 2
- 230000007704 transition Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- WHTVZRBIWZFKQO-AWEZNQCLSA-N (S)-chloroquine Chemical compound ClC1=CC=C2C(N[C@@H](C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-AWEZNQCLSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical class OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 239000000120 Artificial Saliva Substances 0.000 description 1
- 108010002913 Asialoglycoproteins Proteins 0.000 description 1
- 208000023275 Autoimmune disease Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 239000002126 C01EB10 - Adenosine Substances 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 241000282461 Canis lupus Species 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 102000000844 Cell Surface Receptors Human genes 0.000 description 1
- 108010001857 Cell Surface Receptors Proteins 0.000 description 1
- 241001232809 Chorista Species 0.000 description 1
- 102100022641 Coagulation factor IX Human genes 0.000 description 1
- 108010051219 Cre recombinase Proteins 0.000 description 1
- 108010042126 Creatine kinase Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 210000004128 D cell Anatomy 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 206010012438 Dermatitis atopic Diseases 0.000 description 1
- 206010012442 Dermatitis contact Diseases 0.000 description 1
- 102000001039 Dystrophin Human genes 0.000 description 1
- 101150029662 E1 gene Proteins 0.000 description 1
- 101150005585 E3 gene Proteins 0.000 description 1
- 206010053177 Epidermolysis Diseases 0.000 description 1
- 108010076282 Factor IX Proteins 0.000 description 1
- 206010016654 Fibrosis Diseases 0.000 description 1
- 108090000331 Firefly luciferases Proteins 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 208000005176 Hepatitis C Diseases 0.000 description 1
- 102000003745 Hepatocyte Growth Factor Human genes 0.000 description 1
- 108090000100 Hepatocyte Growth Factor Proteins 0.000 description 1
- 241000709721 Hepatovirus A Species 0.000 description 1
- 102000002265 Human Growth Hormone Human genes 0.000 description 1
- 108010000521 Human Growth Hormone Proteins 0.000 description 1
- 239000000854 Human Growth Hormone Substances 0.000 description 1
- 241000701109 Human adenovirus 2 Species 0.000 description 1
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 1
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 1
- 102100023970 Keratin, type I cytoskeletal 10 Human genes 0.000 description 1
- 208000001126 Keratosis Diseases 0.000 description 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 1
- 102000007330 LDL Lipoproteins Human genes 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 1
- 206010027336 Menstruation delayed Diseases 0.000 description 1
- 101150076359 Mhc gene Proteins 0.000 description 1
- 101001137641 Mus musculus Kinase suppressor of Ras 1 Proteins 0.000 description 1
- 101100236491 Mus musculus Manbal gene Proteins 0.000 description 1
- 108091061960 Naked DNA Proteins 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- 206010061306 Nasopharyngeal cancer Diseases 0.000 description 1
- 239000000020 Nitrocellulose Substances 0.000 description 1
- 102000019040 Nuclear Antigens Human genes 0.000 description 1
- 108010051791 Nuclear Antigens Proteins 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 208000005775 Parakeratosis Diseases 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000009328 Perro Species 0.000 description 1
- BELBBZDIHDAJOR-UHFFFAOYSA-N Phenolsulfonephthalein Chemical compound C1=CC(O)=CC=C1C1(C=2C=CC(O)=CC=2)C2=CC=CC=C2S(=O)(=O)O1 BELBBZDIHDAJOR-UHFFFAOYSA-N 0.000 description 1
- 108010039918 Polylysine Proteins 0.000 description 1
- 241001505332 Polyomavirus sp. Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 108091034057 RNA (poly(A)) Proteins 0.000 description 1
- 108700005075 Regulator Genes Proteins 0.000 description 1
- 208000006265 Renal cell carcinoma Diseases 0.000 description 1
- 206010039793 Seborrhoeic dermatitis Diseases 0.000 description 1
- CWHJIJJSDGEHNS-MYLFLSLOSA-N Senegenin Chemical compound C1[C@H](O)[C@H](O)[C@@](C)(C(O)=O)[C@@H]2CC[C@@]3(C)C(CC[C@]4(CCC(C[C@H]44)(C)C)C(O)=O)=C4[C@@H](CCl)C[C@@H]3[C@]21C CWHJIJJSDGEHNS-MYLFLSLOSA-N 0.000 description 1
- 206010040851 Skin fragility Diseases 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 241000529895 Stercorarius Species 0.000 description 1
- 239000004809 Teflon Substances 0.000 description 1
- 229920006362 Teflon® Polymers 0.000 description 1
- 108090001027 Troponin Proteins 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 108010067390 Viral Proteins Proteins 0.000 description 1
- 235000018936 Vitellaria paradoxa Nutrition 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 229960005305 adenosine Drugs 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 230000004931 aggregating effect Effects 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- 208000002029 allergic contact dermatitis Diseases 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003321 amplification Effects 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 239000003098 androgen Substances 0.000 description 1
- 206010068168 androgenetic alopecia Diseases 0.000 description 1
- 210000004102 animal cell Anatomy 0.000 description 1
- 230000003540 anti-differentiation Effects 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000036773 apocrine secretion Effects 0.000 description 1
- 238000003782 apoptosis assay Methods 0.000 description 1
- 239000002473 artificial blood Substances 0.000 description 1
- 201000008937 atopic dermatitis Diseases 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000003115 biocidal effect Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000005540 biological transmission Effects 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 230000036770 blood supply Effects 0.000 description 1
- 210000000746 body region Anatomy 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000010001 cellular homeostasis Effects 0.000 description 1
- 230000030570 cellular localization Effects 0.000 description 1
- 210000003679 cervix uteri Anatomy 0.000 description 1
- 229960003677 chloroquine Drugs 0.000 description 1
- WHTVZRBIWZFKQO-UHFFFAOYSA-N chloroquine Natural products ClC1=CC=C2C(NC(C)CCCN(CC)CC)=CC=NC2=C1 WHTVZRBIWZFKQO-UHFFFAOYSA-N 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 208000019425 cirrhosis of liver Diseases 0.000 description 1
- 239000000512 collagen gel Substances 0.000 description 1
- 201000004196 common wart Diseases 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 230000003750 conditioning effect Effects 0.000 description 1
- 239000000039 congener Substances 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 210000001608 connective tissue cell Anatomy 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 230000030944 contact inhibition Effects 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 239000002537 cosmetic Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 238000005336 cracking Methods 0.000 description 1
- 238000009402 cross-breeding Methods 0.000 description 1
- 238000012136 culture method Methods 0.000 description 1
- 230000001186 cumulative effect Effects 0.000 description 1
- 238000013016 damping Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 229920006237 degradable polymer Polymers 0.000 description 1
- 238000000326 densiometry Methods 0.000 description 1
- 239000005548 dental material Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 230000035617 depilation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 210000001163 endosome Anatomy 0.000 description 1
- 108010048367 enhanced green fluorescent protein Proteins 0.000 description 1
- 210000003158 enteroendocrine cell Anatomy 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 201000004306 epidermodysplasia verruciformis Diseases 0.000 description 1
- 210000005081 epithelial layer Anatomy 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 229960004222 factor ix Drugs 0.000 description 1
- 230000004720 fertilization Effects 0.000 description 1
- 230000004761 fibrosis Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 244000144992 flock Species 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 210000001061 forehead Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000005194 fractionation Methods 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 230000008014 freezing Effects 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 238000001476 gene delivery Methods 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 235000003869 genetically modified organism Nutrition 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 229960002989 glutamic acid Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 210000000224 granular leucocyte Anatomy 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000000569 greater omentum Anatomy 0.000 description 1
- 238000000227 grinding Methods 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 230000003676 hair loss Effects 0.000 description 1
- 230000036074 healthy skin Effects 0.000 description 1
- 210000003677 hemocyte Anatomy 0.000 description 1
- 229940000351 hemocyte Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 210000003630 histaminocyte Anatomy 0.000 description 1
- 239000012510 hollow fiber Substances 0.000 description 1
- 230000036736 holocrine secretion Effects 0.000 description 1
- 238000000265 homogenisation Methods 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 239000000017 hydrogel Substances 0.000 description 1
- GPRLSGONYQIRFK-UHFFFAOYSA-N hydron Chemical compound [H+] GPRLSGONYQIRFK-UHFFFAOYSA-N 0.000 description 1
- YQYJSBFKSSDGFO-FWAVGLHBSA-N hygromycin A Chemical compound O[C@H]1[C@H](O)[C@H](C(=O)C)O[C@@H]1Oc1ccc(\C=C(/C)C(=O)N[C@@H]2[C@@H]([C@H]3OCO[C@H]3[C@@H](O)[C@@H]2O)O)cc1O YQYJSBFKSSDGFO-FWAVGLHBSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000009399 inbreeding Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 210000004969 inflammatory cell Anatomy 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 238000003780 insertion Methods 0.000 description 1
- 230000037431 insertion Effects 0.000 description 1
- 238000002743 insertional mutagenesis Methods 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 210000002664 langerhans' cell Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 238000011694 lewis rat Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000011068 loading method Methods 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 206010025135 lupus erythematosus Diseases 0.000 description 1
- 210000003563 lymphoid tissue Anatomy 0.000 description 1
- 239000012139 lysis buffer Substances 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 210000004379 membrane Anatomy 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 210000002418 meninge Anatomy 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229960000485 methotrexate Drugs 0.000 description 1
- CXKWCBBOMKCUKX-UHFFFAOYSA-M methylene blue Chemical compound [Cl-].C1=CC(N(C)C)=CC2=[S+]C3=CC(N(C)C)=CC=C3N=C21 CXKWCBBOMKCUKX-UHFFFAOYSA-M 0.000 description 1
- 229960000907 methylthioninium chloride Drugs 0.000 description 1
- 244000005700 microbiome Species 0.000 description 1
- 210000002500 microbody Anatomy 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 239000003226 mitogen Substances 0.000 description 1
- 230000009456 molecular mechanism Effects 0.000 description 1
- 230000002969 morbid Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 210000000214 mouth Anatomy 0.000 description 1
- 210000003887 myelocyte Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 210000000653 nervous system Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 210000002445 nipple Anatomy 0.000 description 1
- 229920001220 nitrocellulos Polymers 0.000 description 1
- 230000037311 normal skin Effects 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 238000003199 nucleic acid amplification method Methods 0.000 description 1
- 238000007899 nucleic acid hybridization Methods 0.000 description 1
- 210000001706 olfactory mucosa Anatomy 0.000 description 1
- 238000002515 oligonucleotide synthesis Methods 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 210000004923 pancreatic tissue Anatomy 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000505 pernicious effect Effects 0.000 description 1
- 210000004332 phalangeal cell Anatomy 0.000 description 1
- 239000008177 pharmaceutical agent Substances 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 229960003531 phenolsulfonphthalein Drugs 0.000 description 1
- DYUMLJSJISTVPV-UHFFFAOYSA-N phenyl propanoate Chemical compound CCC(=O)OC1=CC=CC=C1 DYUMLJSJISTVPV-UHFFFAOYSA-N 0.000 description 1
- 229930029653 phosphoenolpyruvate Natural products 0.000 description 1
- DTBNBXWJWCWCIK-UHFFFAOYSA-N phosphoenolpyruvic acid Chemical compound OC(=O)C(=C)OP(O)(O)=O DTBNBXWJWCWCIK-UHFFFAOYSA-N 0.000 description 1
- 239000013600 plasmid vector Substances 0.000 description 1
- 231100000614 poison Toxicity 0.000 description 1
- 230000007096 poisonous effect Effects 0.000 description 1
- 239000004417 polycarbonate Substances 0.000 description 1
- 229920000515 polycarbonate Polymers 0.000 description 1
- 229920000728 polyester Polymers 0.000 description 1
- 229920000656 polylysine Polymers 0.000 description 1
- 238000003752 polymerase chain reaction Methods 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001343 polytetrafluoroethylene Polymers 0.000 description 1
- 239000004810 polytetrafluoroethylene Substances 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000005522 programmed cell death Effects 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000019633 pungent taste Nutrition 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000004445 quantitative analysis Methods 0.000 description 1
- 238000003127 radioimmunoassay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000001172 regenerating effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 108010028349 saliva Orthana Proteins 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 210000004761 scalp Anatomy 0.000 description 1
- 238000003345 scintillation counting Methods 0.000 description 1
- 238000007790 scraping Methods 0.000 description 1
- 210000001732 sebaceous gland Anatomy 0.000 description 1
- 208000008742 seborrheic dermatitis Diseases 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 230000011218 segmentation Effects 0.000 description 1
- 238000005204 segregation Methods 0.000 description 1
- 230000008786 sensory perception of smell Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000009958 sewing Methods 0.000 description 1
- 210000002107 sheath cell Anatomy 0.000 description 1
- 230000003584 silencer Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 206010040882 skin lesion Diseases 0.000 description 1
- 231100000444 skin lesion Toxicity 0.000 description 1
- 201000010153 skin papilloma Diseases 0.000 description 1
- 231100000019 skin ulcer Toxicity 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000009331 sowing Methods 0.000 description 1
- 230000024642 stem cell division Effects 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000005728 strengthening Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000008093 supporting effect Effects 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003356 suture material Substances 0.000 description 1
- 210000004243 sweat Anatomy 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000001360 synchronised effect Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000009871 tenuigenin Substances 0.000 description 1
- BFKJFAAPBSQJPD-UHFFFAOYSA-N tetrafluoroethene Chemical group FC(F)=C(F)F BFKJFAAPBSQJPD-UHFFFAOYSA-N 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- 239000004753 textile Substances 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000003813 thin hair Effects 0.000 description 1
- 238000012090 tissue culture technique Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 239000012745 toughening agent Substances 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000009423 ventilation Methods 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 230000017613 viral reproduction Effects 0.000 description 1
- 239000013603 viral vector Substances 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/0018—Culture media for cell or tissue culture
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Chemical & Material Sciences (AREA)
- Zoology (AREA)
- Organic Chemistry (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Cell Biology (AREA)
- Microbiology (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Plant Pathology (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/IL2001/000976 WO2003035851A1 (fr) | 2001-10-23 | 2001-10-23 | Micro-organes in vitro, et utilisations correspondantes |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010105147771A Division CN102010851A (zh) | 2001-10-23 | 2001-10-23 | 体外微器官及其相关用途 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1582330A true CN1582330A (zh) | 2005-02-16 |
Family
ID=32676735
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CNA018239064A Pending CN1582330A (zh) | 2001-10-23 | 2001-10-23 | 体外微器官及其相关用途 |
Country Status (5)
| Country | Link |
|---|---|
| JP (1) | JP2005506084A (fr) |
| KR (2) | KR100970195B1 (fr) |
| CN (1) | CN1582330A (fr) |
| CA (1) | CA2464460A1 (fr) |
| IL (1) | IL161472A0 (fr) |
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101743472B (zh) * | 2007-05-18 | 2014-09-17 | 生命线科学公司 | 检测器官系统干扰的离体方法 |
| CN104411318A (zh) * | 2011-12-23 | 2015-03-11 | 人类起源公司 | 包含脱细胞并再群体化的胎盘血管支架的类器官 |
| CN105334196A (zh) * | 2015-09-24 | 2016-02-17 | 华东师范大学 | 一种检测3D类器官中P-gp介导的Rh123转运的方法及应用 |
| CN109082402A (zh) * | 2018-08-06 | 2018-12-25 | 复旦大学 | 一种aav-dj型腺相关病毒体外高效感染类器官的用途 |
| CN113774018A (zh) * | 2021-08-30 | 2021-12-10 | 吉林大学 | 一种大鼠心肌细胞和心肌成纤维细胞分离和培养的方法 |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8501396B2 (en) | 2001-11-05 | 2013-08-06 | Medgenics Medical Israel Ltd. | Dermal micro-organs, methods and apparatuses for producing and using the same |
| US7468242B2 (en) | 2001-11-05 | 2008-12-23 | Medgenics, Inc. | Dermal micro organs, methods and apparatuses for producing and using the same |
| US8088568B2 (en) | 2001-11-05 | 2012-01-03 | Medgentics, Inc. | Dermal micro-organs, methods and apparatuses for producing and using the same |
| CA2788000C (fr) | 2003-05-01 | 2016-03-15 | Medgenics Inc. | Appareil pour le prelevement de micro-organes dermiques |
| CN102886052B (zh) | 2006-09-14 | 2014-07-30 | 迈德詹尼克斯医疗以色列有限公司 | 长效药物制剂 |
| US8454948B2 (en) | 2006-09-14 | 2013-06-04 | Medgenics Medical Israel Ltd. | Long lasting drug formulations |
| CA2802726A1 (fr) * | 2010-06-15 | 2011-12-22 | Medgenics Medical Israel Ltd. | Formulations pharmaceutiques a longue duree |
| KR20190042747A (ko) * | 2011-06-02 | 2019-04-24 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 생체외 조직 배양 시스템을 위한 방법 및 용도 |
| RU2631005C1 (ru) * | 2016-10-06 | 2017-09-15 | Федеральное государственное бюджетное образовательное учреждение высшего образования "Российский национальный исследовательский медицинский университет им. Н.И. Пирогова" Министерства здравоохранения Российской Федерации (ФГБОУ ВО РНИМУ им. Н.И. Пирогова Минздрава России) | Способ культивирования клеток слюнной железы человека |
-
2001
- 2001-10-23 JP JP2003538352A patent/JP2005506084A/ja active Pending
- 2001-10-23 IL IL16147201A patent/IL161472A0/xx unknown
- 2001-10-23 CN CNA018239064A patent/CN1582330A/zh active Pending
- 2001-10-23 KR KR1020097010888A patent/KR100970195B1/ko not_active IP Right Cessation
- 2001-10-23 KR KR10-2004-7006068A patent/KR20040070343A/ko active Application Filing
- 2001-10-23 CA CA002464460A patent/CA2464460A1/fr not_active Abandoned
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101743472B (zh) * | 2007-05-18 | 2014-09-17 | 生命线科学公司 | 检测器官系统干扰的离体方法 |
| CN104411318A (zh) * | 2011-12-23 | 2015-03-11 | 人类起源公司 | 包含脱细胞并再群体化的胎盘血管支架的类器官 |
| CN105334196A (zh) * | 2015-09-24 | 2016-02-17 | 华东师范大学 | 一种检测3D类器官中P-gp介导的Rh123转运的方法及应用 |
| CN109082402A (zh) * | 2018-08-06 | 2018-12-25 | 复旦大学 | 一种aav-dj型腺相关病毒体外高效感染类器官的用途 |
| CN109082402B (zh) * | 2018-08-06 | 2021-08-17 | 复旦大学 | 一种aav-dj型腺相关病毒体外高效感染类器官的用途 |
| CN113774018A (zh) * | 2021-08-30 | 2021-12-10 | 吉林大学 | 一种大鼠心肌细胞和心肌成纤维细胞分离和培养的方法 |
| CN113774018B (zh) * | 2021-08-30 | 2023-09-05 | 吉林大学 | 一种大鼠心肌细胞和心肌成纤维细胞分离和培养的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| CA2464460A1 (fr) | 2003-05-01 |
| JP2005506084A (ja) | 2005-03-03 |
| IL161472A0 (en) | 2004-09-27 |
| KR20090060381A (ko) | 2009-06-11 |
| KR20040070343A (ko) | 2004-08-07 |
| KR100970195B1 (ko) | 2010-07-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2813467B2 (ja) | 細胞培養法および培地 | |
| Osada et al. | Long-term culture of mouse vibrissal dermal papilla cells and de novo hair follicle induction | |
| CN100347293C (zh) | 来源于单核细胞的去分化的可程序化干细胞及其制备和应用 | |
| CN1197960C (zh) | 无限增殖的人角质细胞系 | |
| US20100247498A1 (en) | In vitro micro-organs, and uses related thereto | |
| KR101970634B1 (ko) | 생체외 조직 배양 시스템을 위한 방법 및 용도 | |
| US20120004642A1 (en) | In vitro micro-organs, and uses related thereto | |
| CN1582330A (zh) | 体外微器官及其相关用途 | |
| US5625127A (en) | Extended human hematopoiesis in a heterologous host | |
| CA2606983A1 (fr) | Procede de preparation d'un organe a transplanter | |
| Seach et al. | Vascularized tissue engineering mouse chamber model supports thymopoiesis of ectopic thymus tissue grafts | |
| US20030157074A1 (en) | Vitro micro-organs, and uses related thereto | |
| EP1306426A1 (fr) | Micro-organes in vitro et leurs utilisations | |
| US20030152909A1 (en) | In vitro micro-organs, and uses related thereto | |
| WO2004078916A2 (fr) | Micro-organes in vitro, et utilisations correspondantes | |
| CN1662644A (zh) | 制备人β细胞系的方法 | |
| CN101029303A (zh) | 一种诱导干细胞向软骨分化的物质和方法 | |
| CN102010851A (zh) | 体外微器官及其相关用途 | |
| JP2008306938A (ja) | 毛乳頭細胞培養方法 | |
| AU2007229367B2 (en) | In Vitro Micro-Organs and Uses Related Thereto | |
| AU2003271042B2 (en) | In Vitro Micro-Organs and Uses Related Thereto | |
| US20080063629A1 (en) | Method for production of neutrophils and uses therefor | |
| WO2022244502A1 (fr) | Cellules ayant la capacité d'induire des appendices cutanés, et leur procédé de production | |
| CN1863907A (zh) | 毛乳头细胞制品的制备方法、用于再生毛囊的组合物、方法、以及附载着经再生毛囊的动物 | |
| IL161472A (en) | In vitro genetically modified micro-organs expressing a blood clotting factor and uses related thereto |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C12 | Rejection of a patent application after its publication | ||
| RJ01 | Rejection of invention patent application after publication |
Open date: 20050216 |